Nijholt, Kirsten T.
Sánchez-Aguilera, Pablo I.
Booij, Harmen G.
Oberdorf-Maass, Silke U.
Dokter, Martin M.
Wolters, Anouk H. G.
Giepmans, Ben N. G.
van Gilst, Wiek H.
Brown, Joan H.
de Boer, Rudolf A.
Silljé, Herman H. W.
Westenbrink, B. Daan
Funding for this research was provided by:
ZonMw (91111.006)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (184.034.014, 016.176.147)
Hartstichting (2020-8005, 2019T064)
European Research Council (818715)
Article History
Received: 27 October 2022
Accepted: 24 February 2023
First Online: 10 March 2023
Competing interests
: The UMCG, which employs Nijholt, Sánchez-Aguilera, Booij, Oberdorf-Maas, Dokter, Wolters, Giepmans, van Gilst, de Boer, Silljé and Westenbrink, has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Dr. de Boer reports having received speaker fees from Abbott, AstraZeneca, Bayer, Novartis and Roche. All other authors have no competing interests.